Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen

This study has been completed.

Sponsor:

Information provided by:

VA Office of Research and Development

ClinicalTrials.gov Identifier:

NCT00018343

First received: July 3, 2001

Last updated: January 20, 2009

Last verified: December 2004

History of Changes

Purpose

This study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with Alzheimer's Disease.

Condition	Intervention	Phase
Alzheimer's Disease	Drug: estrogen	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease

U.S. FDA Resources

Further study details as provided by VA Office of Research and Development:


Study Start Date:	April 1998
Estimated Study Completion Date:	March 2001

Eligibility


Ages Eligible for Study:	50 Years to 90 Years (Adult, Senior)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Post menopausal women with alzheimer's disease
free of any major medical or neurological disease,
medically safe to be treated with estrogen.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018343

Locations


United States, Washington
VA Puget Sound Health Care System
Lakewood, Washington, United States, 98493-5000

Sponsors and Collaborators

VA Office of Research and Development

Investigators


OverallOfficial:	Suzanne Craft, Ph.D
OverallOfficial:	Laura Baker, Ph.D
OverallOfficial:	Murray Raskind, M.D.

More Information


ClinicalTrials.gov Identifier:	NCT00018343 History of Changes
Other Study ID Numbers:	AGCG-007-97F
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:


Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases	Neurocognitive Disorders Mental Disorders Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 30, 2016

To Top